Statement: Several adverse events which occurred in the primary trial were not heart related.
Primary_evidence: Adverse Events 1:   Total: 58/438 (13.24%)   Febrile neutropenia  13/438 (2.97%)   Neutropenia  5/438 (1.14%)   Anaemia  0/438 (0.00%)   Thrombocytopenia  0/438 (0.00%)   Haemolytic anaemia  1/438 (0.23%)   Leukopenia  1/438 (0.23%)   Cardiac failure congestive  0/438 (0.00%)   Supraventricular tachycardia  0/438 (0.00%)   Myocardial infarction  1/438 (0.23%)   Vertigo  0/438 (0.00%) Adverse Events 2:   Total: 56/437 (12.81%)   Febrile neutropenia  10/437 (2.29%)   Neutropenia  7/437 (1.60%)   Anaemia  2/437 (0.46%)   Thrombocytopenia  1/437 (0.23%)   Haemolytic anaemia  0/437 (0.00%)   Leukopenia  0/437 (0.00%)   Cardiac failure congestive  3/437 (0.69%)   Supraventricular tachycardia  1/437 (0.23%)   Myocardial infarction  0/437 (0.00%)   Vertigo  1/437 (0.23%)